Trials Sponsors Conditions Drugs Pricing

Conditions

Nociceptive Pain Peripheral Neuropathic Pain

Keywords

Allodyniahyperalgesiaparesthesia

Outcome Measures

Primary Outcomes (1)

Results of mechanical pain testing using Quantitative Sensory Testing
Day 1

Secondary Outcomes (4)

Number of participants with Adverse Events
Range of 14 days
Vital signs
Day 1
Clinical chemistry (urinalysis, hematology)
At follow up (a range of 8-15 days after Day 1)
The effect of AZD3161 on axon reflex flare in normal and UVC irradiated skin using a Laser doppler scan
Day 1

Study Arms (5)

1

EXPERIMENTAL

150 μL intradermal injection of 1 μmol/L AZD3161

Drug: AZD3161

2

EXPERIMENTAL

150 μL intradermal injection of 6 μmol/L AZD3161

Drug: AZD3161

3

EXPERIMENTAL

150 μL intradermal injection of 30 μmol/L AZD3161

Drug: AZD3161

Interventions

AZD3161Drug

Single dose, intradermal injection

123

LidocaineDrug

Single dose, intradermal injection

Eligibility Criteria

Age18 Years - 55 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Healthy Caucasian male and female volunteers aged 18 to 55 years inclusive with suitable veins for venepuncture
The subject belongs to skin type II or III according to Fitzpatrick skin type scale

Sponsors & Collaborators

AstraZeneca
Industrylead

Study Sites (1)

Research Site

London, United Kingdom

MeSH Terms

Conditions

Nociceptive PainHyperalgesiaParesthesia

Interventions

Lidocaine

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSomatosensory DisordersSensation DisordersNervous System Diseases

Intervention Hierarchy (Ancestors)

AcetanilidesAnilides

Study Officials

Darren Wilbraham, MD, MBBS DCPSA
Quintiles Drug Research Unit at Guy's Hospital
PRINCIPAL INVESTIGATOR
Bo Fransson
AstraZeneca R&D
STUDY CHAIR

Enrollment

26 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

November 10, 2010

First Posted

November 15, 2010

Study Start

December 2010

Date type not reported

This date has not been verified as actual or estimated.

Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (4)

Study Arms (5)

1

2

3

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

4

5

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (4)

Study Arms (5)

1

2

3

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

4

5

You may not qualify if:

Source record

Locations